{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:19:04Z","timestamp":1773015544941,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16H06280"],"award-info":[{"award-number":["JP16H06280"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["20FC1030"],"award-info":[{"award-number":["20FC1030"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.msard.2022.104077","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T20:23:41Z","timestamp":1658780621000},"page":"104077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["High-efficacy therapy reduces subcortical grey matter volume loss in Japanese patients with relapse-onset multiple sclerosis: A 2-year cohort study"],"prefix":"10.1016","volume":"67","author":[{"given":"Hiroaki","family":"Yokote","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusei","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuta","family":"Toru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Niino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Sanjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104077_bib0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2017.03.009","article-title":"Whole brain and grey matter volume of Japanese patients with multiple sclerosis","volume":"306","author":"Akaishi","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2022.104077_bib0021","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ana.25150","article-title":"Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease","volume":"83","author":"Azevedo","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.104077_bib0022","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1198\/000313006X90684","article-title":"Symmetrized percent change for treatment comparisons","volume":"60","author":"Berry","year":"2006","journal-title":"Am. Stat."},{"key":"10.1016\/j.msard.2022.104077_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149685","article-title":"The effect of disease-modifying drugs on brain atrophy in relapsing-remitting multiple sclerosis: a meta-analysis","volume":"11","author":"Branger","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2022.104077_bib0024","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2022.104077_bib0025","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104077_bib0026","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1136\/bmj.j3663","article-title":"Statistics Notes: what is a percentage difference?","volume":"358","author":"Cole","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2022.104077_bib0027","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/brain\/awy088","article-title":"Progression of regional grey matter atrophy in multiple sclerosis","volume":"141","author":"Eshaghi","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.msard.2022.104077_bib0028","doi-asserted-by":"crossref","first-page":"11050","DOI":"10.1073\/pnas.200033797","article-title":"Measuring the thickness of the human cerebral cortex from magnetic resonance images","volume":"97","author":"Fischl","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.msard.2022.104077_bib0029","first-page":"1","article-title":"Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis","author":"Harding","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2022.104077_bib0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2022.104077_bib0031","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/ene.14335","article-title":"Comparison of brain atrophy in patients with multiple sclerosis treated with first- versus second-generation disease modifying therapy without clinical relapse","volume":"27","author":"Masuda","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.104077_bib0032","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3174\/ajnr.A5459","article-title":"Reproducibility of deep gray matter atrophy rate measurement in a large multicenter dataset","volume":"39","author":"Meijerman","year":"2018","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.msard.2022.104077_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2342-11-3","article-title":"Lin4Neuro: a customized Linux distribution ready for neuroimaging analysis","volume":"25","author":"Nemoto","year":"2011","journal-title":"BMC Med. Imaging"},{"key":"10.1016\/j.msard.2022.104077_bib0034","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00415-015-7637-3","article-title":"Multiple sclerosis in Japan appears to be a milder disease compared to the UK","volume":"262","author":"Piccolo","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104077_bib0035","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/1352458519826364","article-title":"Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis","volume":"26","author":"Sotirchos","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.104077_bib0036","first-page":"1","article-title":"The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis","volume":"10","author":"Tsivgoulis","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2022.104077_bib0037","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1177\/1352458512473190","article-title":"Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes","volume":"19","author":"Vidal-Jordana","year":"2013","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.104077_bib0038","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/01.wnl.0000316810.01120.05","article-title":"Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis","volume":"71","author":"Zivadinov","year":"2008","journal-title":"Neurolgy"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:49Z","timestamp":1761901489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822005855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":19,"alternative-id":["S2211034822005855"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104077","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-efficacy therapy reduces subcortical grey matter volume loss in Japanese patients with relapse-onset multiple sclerosis: A 2-year cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104077"}}